Arvinas, Inc. (ARVN) Balance Sheet

The contraction is driven primarily by the unwinding of liabilities, notably deferred revenue falling from $599.2M to zero, which suggests collaboration prepayments are being recognized rather than replaced. Equity has also declined from $600.1M to $513.8M despite the recent profitable quarter, indicating that the accumulated deficit of roughly $1.6B continues to weigh on book value. Investors should monitor whether the asset base stabilizes or continues to decline as partnership cash is deployed.

The high current ratio largely reflects the near-absence of current liabilities following the release of deferred revenue, rather than an unusually large liquid asset pool. Cash of $88.0M, compared with quarterly operating cash burn that has frequently exceeded several tens of millions, suggests limited runway absent new partnership inflows. Investors should monitor cash levels closely given the reliance on episodic collaboration payments.

Debt has declined from $1.5M in 2024Q3 peak-era levels to a modest $7.6M, and it is not a meaningful source of financing risk relative to the equity base. The absence of material leverage means the balance sheet's vulnerability lies in operating cash consumption rather than debt service. This suggests refinancing pressure is unlikely to be the binding constraint on the business.

The large negative retained earnings indicate that cumulative losses have consumed most of the capital raised historically, a pattern typical of clinical-stage biotechnology with heavy R&D spend. Share repurchases of $74.1M in 2025Q4 and $17.8M in 2025Q3, made while operating cash flow was negative, may warrant further investigation as to their funding source and capital allocation rationale. Investors should weigh whether these buybacks represent confidence or a misallocation of scarce cash.